GenSight Biologics S.A.

GenSight Biologics S.A. is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative gene therapies. The company's core mission is to translate scientific advancements in gene therapy into effective treatments for patients suffering from severe inherited diseases of the eye and central nervous system, with an initial focus on preserving or restoring vision. Headquartered in Paris, France, GenSight Biologics was founded in 2012 as a spin-off from the Institut de la Vision.

GenSight Biologics leverages two primary technology platforms: Mitochondrial Targeting Sequence (MTS) and optogenetics. Its pipeline includes lead product candidates such as GS010 (lenadogene nolparvovec), which is in Phase III clinical development for Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease causing irreversible blindness. Another key candidate, GS030, combines gene therapy with optogenetics and is in Phase I/II clinical development for retinitis pigmentosa. These product candidates are designed for single intravitreal injection to provide patients with sustainable functional visual recovery.

Under the leadership of CEO Laurence Rodriguez, GenSight Biologics continues to advance its clinical programs and market positioning. In March 2026, the company successfully closed a fundraising round of nearly €1.7 million and reported a cash position of €3.2 million as of March 31, 2026. The company is actively progressing with early access programs for GS010/LUMEVOQ in France, Israel, and the USA, and the REVISE study is ongoing. GenSight Biologics is publicly traded on Euronext Paris under the ticker symbol SIGHT.